United Guardian (UG) Free Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
United Guardian (UG) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.54 Bn | 626.78 Bn | 17.26 Bn | 33.62% |
| 2 | AbbVie | 441.45 Bn | 434.88 Bn | 12.70 Bn | -20.26% |
| 3 | Merck | 364.78 Bn | 357.64 Bn | 12.21 Bn | 17.80% |
| 4 | Novartis Ag | 267.01 Bn | 259.32 Bn | 11.24 Bn | 17.73% |
| 5 | Pfizer | 158.95 Bn | 147.25 Bn | 10.94 Bn | 28.91% |
| 6 | Sanofi | 52.54 Bn | 45.16 Bn | 10.79 Bn | 56.97% |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - | - |
| 8 | Incyte | 25.36 Bn | 20.82 Bn | 1.57 Bn | 18.29% |
| 9 | United Therapeutics | 21.31 Bn | 18.65 Bn | 683.80 Mn | 49.44% |
| 10 | United Guardian | 32.95 Mn | 23.36 Mn | 1.55 Mn | 51.30% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 51.30% |
| Mar 31, 2026 | 12.74% |
| Dec 31, 2025 | -20.36% |
| Sep 30, 2025 | 13.12% |
| Jun 30, 2025 | -36.77% |
| Mar 31, 2025 | 141.63% |
| Dec 31, 2024 | -26.58% |
| Sep 30, 2024 | 6.63% |
| Jun 30, 2024 | -8.00% |
| Mar 31, 2024 | -13.52% |
| Dec 31, 2023 | 16.47% |
| Sep 30, 2023 | 80.26% |
| Jun 30, 2023 | -38.84% |
| Mar 31, 2023 | -31.41% |
| Dec 31, 2022 | -10.13% |
| Sep 30, 2022 | -8.94% |
| Jun 30, 2022 | 1.12% |
| Mar 31, 2022 | -75.41% |
| Dec 31, 2021 | 16.41% |
| Sep 30, 2021 | -5.37% |